Isolation of Hymenolepis diminuta cysticercoids for therapeutic use: The need for fully disclosed methodology
Open Access
- 17 September 2026
- journal article
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 1334
Abstract
Background Helminth therapy holds considerable theoretical promise for clinical and public health applications. Unfortunately, clinical trials have often used helminths produced using methods that are both highly variable and insufficiently described in the literature, which may hinder reproducibility and troubleshooting. This study aimed to devise a method for purification of helminths that avoids mechanical filtration, which may damage some organisms. In particular, the goal was to devise a method to separate large quantities of cysticercoids of the cestode species Hymenolepis diminuta (HDCs), a process that has not been described previously but that would be necessary before HDCs can be used clinically. Methods The physical size and behavior of HDCs in solution were assessed and used to create a patented washing device. Results The cross-sectional area of HDCs varied over a 10-fold range, from approximately 0.06 to 0.6 mm 2 , dependent in large part upon the host. That cross-sectional area correlated in a linear fashion with the steady-state speed of HDCs while falling through solution, which varied over a 5-fold range, from approximately 0.4 mm/s to 2.0 mm/s in the solution tested. These parameters were used to develop a washing device that utilized a variable flow speed dictated by changing column diameter and an upward flowing column of liquid that effectively and simultaneously suspended HDCs of various sizes in a wash solution. Conclusions This study describes a detailed method of purification of HDCs, organisms that could potentially be used for helminth therapy. It is hoped that government agencies or non-profit organizations can use such technology to conduct rigorous clinical trials, potentially leading to the production of reasonably priced therapeutics.Keywords
Funding Information
- Akademie Věd České Republiky
- WPLab
- Tanawisa
- Duke University Medical Center
This publication has 37 references indexed in Scilit:
- COVID-19 morbidity in lower versus higher income populations underscores the need to restore lost biodiversity of eukaryotic symbiontsiScience, 2023
- Socio-medical studies of individuals self-treating with helminths provide insight into clinical trial design for assessing helminth therapyParasitology International, 2022
- Evolution of the hygiene hypothesis into biota alteration theory: what are the paradigms and where are the clinical applications?Microbes and Infection, 2018
- The Intestinal Microbiota Contributes to the Ability of Helminths to Modulate Allergic InflammationImmunity, 2015
- Experimental hookworm infection and gluten microchallenge promote tolerance in celiac diseaseJournal of Allergy and Clinical Immunology, 2015
- Prerequisites for the pharmaceutical industry to develop and commercialise helminths and helminth-derived product therapyInternational Journal for Parasitology, 2013
- Immune monitoring ofTrichuris suisegg therapy in multiple sclerosis patientsJournal of Helminthology, 2011
- Trichuris suis ova therapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trialJournal of Allergy and Clinical Immunology, 2010
- Suppression of Autoimmune Disease in NZB and (NZB×NZW)F1 Hybrid Mice by Infection with MalariaNature, 1970
- AUTOIMMUNE DISEASE AND PARASITIC INFECTIONS IN NIGERIANSThe Lancet, 1968